3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain
4
Colorectal Neoplasms
3
Adenoma
3
Urologic Neoplasms
2
Insulin Resistance
2
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Polycystic Ovary Syndrome
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Mobility Limitation
1
MRSA Colonization
1
Ilues
1
Hypothyroidism
1
Hydronephrosis
1
Head and Neck Neoplasms
1
Fatigue
1
Fasting
1
Disease
1
Depression
1
Colonoscopy
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Standard of Care
9
Cystectomy
8
Early Intervention, Educational
7
Cystoscopy
6
Methods
5
Transurethral Resection of Bladder
4
Practice Guidelines as Topic
4
Multiparametric Magnetic Resonance Imaging
4
Exercise
4
Blood Specimen Collection
4
Anesthesia, General
4
Surgical Procedures, Operative
3
Sevoflurane
3
Radiotherapy, Intensity-Modulated
3
Psychiatric Rehabilitation
3
Gemcitabine
3
Diet Therapy
3
Cisplatin
3
Anesthesia, Spinal
3
Watchful Waiting
2
Ultrasonography
2
Therapeutics
2
Surveys and Questionnaires
2
Specimen Handling
2
Saline Solution
2
Robotic Surgical Procedures
2
Radiotherapy
2
Propofol
2
Preoperative Exercise
2
Palliative Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Urinary Bladder Neoplasms
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled